title: Implantation of a new porous gelatin-siloxane hybrid into a brain lesion as a potential scaffold for tissue regeneration.
abstract: For brain tissue regeneration, any scaffold for migrated or transplanted stem cells with supportive angiogenesis is important once necrotic brain tissue has formed a cavity after injury such as cerebral ischemia. In this study, a new porous gelatin-siloxane hybrid derived from the integration of gelatin and 3-(glycidoxypropyl) trimethoxysilane was implanted as a three-dimensional scaffold into a defect of the cerebral cortex. The porous hybrid implanted into the lesion remained at the same site for 60 days, kept integrity of the brain shape, and attached well to the surrounding brain tissues. Marginal cavities of the scaffolds were occupied by newly formed tissue in the brain, where newly produced vascular endothelial, astroglial, and microglial cells were found with bromodeoxyuridine double positivity, and the numbers of those cells were dose-dependently increased with the addition of basic fibroblast growth factor (bFGF) and epidermal growth factor (EGF). Extension of dendrites was also found from the surrounding cerebral cortex to the newly formed tissue, especially with the addition of bFGF and EGF. The present study showed that a new porous gelatin-siloxane hybrid had biocompatibility after implantation into a lesion of the central nervous system, and thus provided a potential scaffold for cell migration, angiogenesis and dendrite elongation with dose-dependent effects of additive bFGF and EGF.
authors.affiliation: Department of Neurology, Graduate School of Medicine, Dentistry and Pharmacy, Faculty of Engineering, Okayama University, Okayama, Japan. degu@cc.okayama-u.ac.jp
authors.forename: Kentaro
authors.initials: K
authors.lastname: Deguchi
authors.forename: Kanji
authors.initials: K
authors.lastname: Tsuru
authors.forename: Takeshi
authors.initials: T
authors.lastname: Hayashi
authors.forename: Mikiro
authors.initials: M
authors.lastname: Takaishi
authors.forename: Mitsuyuki
authors.initials: M
authors.lastname: Nagahara
authors.forename: Shoko
authors.initials: S
authors.lastname: Nagotani
authors.forename: Yoshihide
authors.initials: Y
authors.lastname: Sehara
authors.forename: Guang
authors.initials: G
authors.lastname: Jin
authors.forename: HanZhe
authors.initials: H
authors.lastname: Zhang
authors.forename: Satoshi
authors.initials: S
authors.lastname: Hayakawa
authors.forename: Mikio
authors.initials: M
authors.lastname: Shoji
authors.forename: Masahiro
authors.initials: M
authors.lastname: Miyazaki
authors.forename: Akiyoshi
authors.initials: A
authors.lastname: Osaka
authors.forename: Nam-Ho
authors.initials: NH
authors.lastname: Huh
authors.forename: Koji
authors.initials: K
authors.lastname: Abe
mesh_terms: D000818:Animals; D001921:Brain / Q000187:drug effects / Q000502:physiology*; D001973:Bromodeoxyuridine; D002465:Cell Movement / Q000187:drug effects; D004815:Epidermal Growth Factor / Q000494:pharmacology; D016222:Fibroblast Growth Factor 2 / Q000494:pharmacology; D005780:Gelatin / Q000008:administration & dosage*; D007150:Immunohistochemistry; D020007:Implants, Experimental; D008297:Male; D010641:Phenotype; D016062:Porosity; D051381:Rats; D017208:Rats, Wistar; D012038:Regeneration / Q000187:drug effects / Q000502:physiology*; D044968:Regenerative Medicine / Q000379:methods*; D012833:Siloxanes / Q000008:administration & dosage*; D023822:Tissue Engineering / Q000379:methods*
chemical_list: D012833:Siloxanes; D016222:Fibroblast Growth Factor 2; D004815:Epidermal Growth Factor; D005780:Gelatin; D001973:Bromodeoxyuridine